Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey

Blood

Volumn 119, Issue 3, 2012, Pages 651-665

  Aggarwal, Bharat B ^a   Gupta, Subash C ^a   Kim, Ji Hye ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; CASPASE 3; CASPASE 9; CD27 ANTIGEN; CD30 ANTIGEN; CD40 LIGAND; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; HLA DR3 ANTIGEN; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; LYMPHOTOXIN; OX40 LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

AMINO ACID SEQUENCE; ANGIOGENESIS; APOPTOSIS; CARDIOVASCULAR DISEASE; HUMAN; INFLAMMATION; LUNG DISEASE; LYMPHOCYTE; MACROPHAGE; METABOLIC DISORDER; METASTASIS; MORPHOGENESIS; MUTATION; NEOPLASM; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TUMOR REGRESSION;

EID: 84862962823     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-325225     Document Type: Review

References (144)

1. Bhardwaj A, Aggarwal BB. Receptor-mediated choreography of life and death. J Clin Immunol. 2003;23(5):317-332. (Pubitemid 37083187)
2. Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol. 2003;66(8): 1403-1408. (Pubitemid 38373326)
3. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3(9):745-756. (Pubitemid 41070815)
4. O'Malley. Action of bacterial polysaccharide on tumors: II. Damage of Sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance. J Natl Cancer Inst. 1962;29:1169-1175.
5. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975;72(9):3666-3670.
6. Aggarwal BB, Moffat B, Harkins RN. Human lymphotoxin: production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem. 1984;259(1):686-691. (Pubitemid 14177684)
7. Aggarwal BB, Henzel WJ, Moffat B, Kohr WJ, Harkins RN. Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line. J Biol Chem. 1985;260(4):2334-2344. (Pubitemid 15104838)
8. Aggarwal BB, Kohr WJ, Hass PE, et al. Human tumor necrosis factor: production, purification, and characterization. J Biol Chem. 1985;260(4): 2345-2354. (Pubitemid 15104839)
9. Bringman TS, Aggarwal BB. Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes. Hybridoma. 1987;6(5):489-507. (Pubitemid 17168068)
10. Kelker HC, Oppenheim JD, Stone-Wolff D, et al. Characterization of human tumor necrosis factor produced by peripheral blood monocytes and its separation from lymphotoxin. Int J Cancer. 1985; 36(1):69-73. (Pubitemid 15028617)
11. Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 1984;312(5996):724-729. (Pubitemid 15195918)
12. Gray PW, Aggarwal BB, Benton CV, et al. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature. 1984;312(5996):721-724. (Pubitemid 15195917)
13. Aggarwal BB, Eessalu TE, Hass PE. Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature. 1985;318(6047):665-667. (Pubitemid 16172416)
14. Beutler B, Greenwald D, Hulmes JD, et al. Identity of tumour necrosis factor and the macrophage- secreted factor cachectin. Nature. 1985; 316(6028):552-554. (Pubitemid 16239366)
15. Cerami A. The value of failure: the discovery of TNF and its natural inhibitor erythropoietin. J Intern Med. 2011;269(1):8-15.
16. Schneider P, Olson D, Tardivel A, et al. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem. 2003;278(7): 5444-5454. (Pubitemid 36801061)
17. Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med. 1999;5(7):828-831. (Pubitemid 29318619)
18. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006; 25(3):409-416.
19. Deroose JP, Eggermont AM, van Geel AN, et al. Long-term results of tumor necrosis factor α- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol. 2011;29(30):4036-4044.
20. Deroose JP, Eggermont AM, van Geel AN, de Wilt JH, Burger JW, Verhoef C. 20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters [published online ahead of print August 31, 2011]. Ann Surg Oncol. doi:10.1245/s10434-011-2030-7.
21. Grunhagen DJ, de Wilt JH, van Geel AN, Verhoef C, Eggermont AM. Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities. Recent Results Cancer Res. 2009;179:257-270.
22. Aggarwal BB, Bhardwaj U, Takada Y. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors. Vitam Horm. 2004; 67:453-483. (Pubitemid 39753674)
23. Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009;457(7232):981-989.
24. .Watts AD, Hunt NH, Wanigasekara Y, et al. A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in "reverse signalling."EMBO J. 1999;18(8):2119-2126. (Pubitemid 29179169)
25. Harashima S, Horiuchi T, Hatta N, et al. Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells. J Immunol. 2001; 166(1):130-136. (Pubitemid 32038425)
26. Wiley SR, Goodwin RG, Smith CA. Reverse signaling via CD30 ligand. J Immunol. 1996;157(8): 3635-3639. (Pubitemid 126449178)
27. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell. 1995;81(4):495-504.
28. Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996;84(2):299-308. (Pubitemid 26042835)
29. Morgan MJ, Liu ZG. Reactive oxygen species in TNFalpha-induced signaling and cell death. Mol Cells. 2010;30(1):1-12.
30. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004;6(3):203-208.
31. Devin A, Cook A, Lin Y, Rodriguez Y, Kelliher M, Liu Z. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity. 2000;12(4):419-429.
32. Natoli G, Costanzo A, Moretti F, Fulco M, Balsano C, Levrero M. Tumor necrosis factor (TNF) receptor 1 signaling downstream of TNF receptor-associated factor 2: nuclear factor kappaB (NFkappaB)- inducing kinase requirement for activation of activating protein 1 and NFkappaB but not of c-Jun N-terminal kinase/stress-activated protein kinase. J Biol Chem. 1997;272(42):26079-26082. (Pubitemid 27458811)
33. Ermolaeva MA, Michallet MC, Papadopoulou N, et al. Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses. Nat Immunol. 2008;9(9): 1037-1046.
34. Desch CE, Dobrina A, Aggarwal BB, Harlan JM. Tumor necrosis factor-alpha exhibits greater proinflammatory activity than lymphotoxin in vitro. Blood. 1990;75(10):2030-2034. (Pubitemid 20180293)
35. Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA Jr, Shepard HM. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science. 1985;230(4728):943-945. (Pubitemid 16193990)
36. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9(5):361-371.
37. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72(11):1605-1621. (Pubitemid 44666739)
38. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3(6):673-682. (Pubitemid 26091143)
39. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446-457.
40. Brietzke E, Kapczinski F. TNF-alpha as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1355-1361. (Pubitemid 352033661)
41. Murashima YL, Suzuki J, Yoshii M. Role of cytokines during epileptogenesis and in the transition from the interictal to the ictal state in the epileptic mutant EL mouse. Gene Regul Syst Bio. 2008;2: 267-274.
42. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry. 2010;68(10):930-941.
43. Nagatsu T, Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des. 2005;11(8):999-1016. (Pubitemid 40331301)
44. Sayed BA, Christy AL, Walker ME, Brown MA. Meningeal mast cells affect early T cell central nervous system infiltration and blood-brain barrier integrity through TNF: a role for neutrophil recruitment? J Immunol. 2010;184(12):6891-6900.
45. Choi C, Gillespie GY, Van Wagoner NJ, Benveniste EN. Fas engagement increases expression of interleukin-6 in human glioma cells. J Neuro-oncol. 2002;56(1):13-19. (Pubitemid 34256613)
46. Kapadia S, Lee J, Torre-Amione G, Birdsall HH, Ma TS, Mann DL. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest. 1995;96(2):1042-1052.
47. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323(4):236-241. (Pubitemid 20225044)
48. Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol. 2000; 35(3):537-544. (Pubitemid 30167009)
49. Diwan A, Tran T, Misra A, Mann DL. Inflammatory mediators and the failing heart: a translational approach. Curr Mol Med. 2003;3(2):161-182. (Pubitemid 36285104)
50. McKellar GE, McCarey DW, Sattar N, McInnes IB. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol. 2009;6(6):410-417.
51. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690-1697.
52. Matera MG, Calzetta L, Cazzola M. TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. Pulm Pharmacol Ther. 2010;23(2):121-128.
53. Kips JC, Tavernier JH, Joos GF, Peleman RA, Pauwels RA. The potential role of tumour necrosis factor alpha in asthma. Clin Exp Allergy. 1993; 23(4):247-250. (Pubitemid 23142763)
54. Lundblad LK, Thompson-Figueroa J, Leclair T, et al. Tumor necrosis factor-alpha overexpression in lung disease: a single cause behind a complex phenotype. Am J Respir Crit Care Med. 2005; 171(12):1363-1370. (Pubitemid 40800508)
55. Collison A, Foster PS, Mattes J. Emerging role of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) as a key regulator of inflammatory responses. Clin Exp Pharmacol Physiol. 2009; 36(11):1049-1053.
56. Schreiber TH, Wolf D, Tsai MS, et al. Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation. J Clin Invest. 2010; 120(10):3629-3640.
57. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87-91. (Pubitemid 23036092)
58. Tzanavari T, Giannogonas P, Karalis KP. TNF-alpha and obesity. Curr Dir Autoimmun. 2010;11: 145-156.
59. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004;25(1): 4-7. (Pubitemid 38032801)
60. Vinay DS, Kwon BS. The tumour necrosis factor/ TNF receptor superfamily: therapeutic targets in autoimmune diseases. Clin Exp Immunol. 2011; 164:145-157.
61. Banks TA, Rouse BT, Kerley MK, et al. Lymphotoxin- alpha-deficient mice: effects on secondary lymphoid organ development and humoral immune responsiveness. J Immunol. 1995;155(4): 1685-1693.
62. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med. 1996; 184(4):1397-1411. (Pubitemid 26354696)
63. Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A. 1997;94(15):8093-8098. (Pubitemid 27343782)
64. Hubert KE, Davies MH, Stempel AJ, Griffith TS, Powers MR. TRAIL-deficient mice exhibit delayed regression of retinal neovascularization. Am J Pathol. 2009;175(6):2697-2708.
65. Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA, Peschon J, Chen YH. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat Immunol. 2003;4(3):255-260. (Pubitemid 36322135)
66. Finnberg N, Gruber JJ, Fei P, et al. DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol. 2005;25(5):2000-2013. (Pubitemid 40280162)
67. Ida H, Kawasaki E, Miyashita T, et al. A novel mutation (T61I) in the gene encoding tumour necrosis factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus. Rheumatology (Oxford). 2004;43(10):1292-1299. (Pubitemid 39359307)
68. Um JY, An NH, Kim HM. TNF-alpha and TNF-beta gene polymorphisms in cerebral infarction. J Mol Neurosci. 2003;21(2):167-171.
69. Boyce EG, Halilovic J, Stan-Ugbene O. Golimumab: review of the efficacy and tolerability of a recently approved tumor necrosis factor-alpha inhibitor. Clin Ther. 2010;32(10):1681-1703.
70. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129(3):807-818. (Pubitemid 41242673)
71. Hartung HP, Kieseier BC. Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord. 2010;3(4):205-216.
72. Genovese MC, Kinnman N, de La Bourdonnaye G, Pena Rossi C, Tak PP. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum. 2011;63(7):1793-1803.
73. van Vollenhoven RF, Kinnman N, Vincent E, Wax S, Bathon J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo- controlled trial. Arthritis Rheum. 2011;63(7): 1782-1792.
74. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem. 1995;270(42):24995-25000.
75. Chan MM. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol. 1995;49(11):1551-1556.
76. Gupta SC, Prasad S, Kim JH, et al. Multitargeting by curcumin as revealed by molecular interaction studies Nat Prod Rep. 2011;28(12):1937-1955.
77. .Wua ST, Suna JC, Leeb KJ, Sunc YM. Docking prediction for tumor necrosis factor-α and five herbal inhibitors. Intl J Eng Sci Technol. 2010;2: 4263-4277.
78. Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. Front Biosci. 2008;13:5094-5107. (Pubitemid 351599660)
79. Song HY, Regnier CH, Kirschning CJ, Goeddel DV, Rothe M. Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci U S A. 1997;94(18): 9792-9796. (Pubitemid 27408143)
80. Yuasa T, Ohno S, Kehrl JH, Kyriakis JM. Tumor necrosis factor signaling to stress-activated protein kinase (SAPK)/Jun NH2-terminal kinase (JNK) and p38: germinal center kinase couples TRAF2 to mitogen-activated protein kinase/ERK kinase kinase 1 and SAPK while receptor interacting protein associates with a mitogen-activated protein kinase kinase kinase upstream of MKK6 and p38. J Biol Chem. 1998;273(35): 22681-22692. (Pubitemid 28399839)
81. Alimzhanov MB, Kuprash DV, Kosco-Vilbois MH, et al. Abnormal development of secondary lymphoid tissues in lymphotoxin beta-deficient mice. Proc Natl Acad Sci U S A. 1997;94(17):9302-9307.
82. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104(4):487-501. (Pubitemid 32201945)
83. Kim N, Odgren PR, Kim DK, Marks SC Jr, Choi Y. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci U S A. 2000;97(20):10905-10910.
84. Varfolomeev E, Kischkel F, Martin F, et al. APRIL-deficient mice have normal immune system development. Mol Cell Biol. 2004;24(3):997-1006. (Pubitemid 38112165)
85. Castigli E, Scott S, Dedeoglu F, et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci U S A. 2004;101(11):3903-3908. (Pubitemid 38381075)
86. Gross JA, Dillon SR, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity. 2001;15(2): 289-302. (Pubitemid 32816877)
87. Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001;293(5537):2111-2114. (Pubitemid 32848063)
88. Monreal AW, Zonana J, Ferguson B. Identification of a new splice form of the EDA1 gene permits detection of nearly all X-linked hypohidrotic ectodermal dysplasia mutations. Am J Hum Genet. 1998;63(2):380-389. (Pubitemid 30418619)
89. Schneider P, Street SL, Gaide O, et al. Mutations leading to X-linked hypohidrotic ectodermal dysplasia affect three major functional domains in the tumor necrosis factor family member ectodysplasin-A. J Biol Chem. 2001;276(22):18819-18827.
90. Newton K, French DM, Yan M, Frantz GD, Dixit VM. Myodegeneration in EDA-A2 transgenic mice is prevented by XEDAR deficiency. Mol Cell Biol. 2004;24(4):1608-1613. (Pubitemid 38167082)
91. Rothe J, Lesslauer W, Lotscher H, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993;364(6440):798-802. (Pubitemid 23261759)
92. Knight B, Yeoh GC, Husk KL, et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med. 2000;192(12):1809-1818. (Pubitemid 32049773)
93. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268(5215):1347-1349.
94. Jacobson BA, Panka DJ, Nguyen KA, Erikson J, Abbas AK, Marshak-Rothstein A. Anatomy of autoantibody production: dominant localization of antibody-producing cells to T cell zones in Fasdeficient mice. Immunity. 1995;3(4):509-519.
95. Singer GG, Abbas AK. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity. 1994;1(5):365-371.
96. Gaspal FM, Kim MY, McConnell FM, Raykundalia C, Bekiaris V, Lane PJ. Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T cell memory. J Immunol. 2005;174(7):3891-3896. (Pubitemid 40395961)
97. Kwon BS, Hurtado JC, Lee ZH, et al. Immune responses in 4-1BB (CD137)-deficient mice. J Immunol. 2002;168(11):5483-5490. (Pubitemid 34556126)
98. Vinay DS, Choi BK, Bae JS, Kim WY, Gebhardt BM, Kwon BS. CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses. J Immunol. 2004;173(6):4218-4229. (Pubitemid 39280788)
99. Lee SW, Park Y, So T, et al. Identification of regulatory functions for 4-1BB and 4-1BBL in myelopoiesis and the development of dendritic cells. Nat Immunol. 2008;9(8):917-926.
100. Jeon HJ, Choi JH, Jung IH, et al. CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. Circulation. 2010;121(9):1124-1133.
101. Girgenrath M, Weng S, Kostek CA, et al. TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J. 2006;25(24):5826-5839. (Pubitemid 44967766)
102. Scholzke MN, Rottinger A, Murikinati S, Gehrig N, Leib C, Schwaninger M. TWEAK regulates proliferation and differentiation of adult neural progenitor cells. Mol Cell Neurosci. 2011;46(1):325-332.
103. Tirnitz-Parker JE, Viebahn CS, Jakubowski A, et al. Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology. 2010;52(1):291-302.
104. Yan M, Wang H, Chan B, et al. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol. 2001;2(7):638-643. (Pubitemid 32677632)
105. Yan M, Brady JR, Chan B, et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol. 2001;11(19):1547-1552. (Pubitemid 32931019)
106. .Wang EC, Thern A, Denzel A, Kitson J, Farrow SN, Owen MJ. DR3 regulates negative selection during thymocyte development. Mol Cell Biol. 2001;21(10):3451-3461. (Pubitemid 32381781)
107. Stephens GL, McHugh RS, Whitters MJ, et al. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol. 2004;173(8): 5008-5020. (Pubitemid 39387783)
108. Pispa J, Pummila M, Barker PA, Thesleff I, Mikkola ML. Edar and Troy signalling pathways act redundantly to regulate initiation of hair follicle development. Hum Mol Genet. 2008;17(21): 3380-3391.
109. Schmidt CS, Liu J, Zhang T, et al. Enhanced B cell expansion, survival, and humoral responses by targeting death receptor 6. J Exp Med. 2003; 197(1):51-62. (Pubitemid 36110257)
110. Zhao H, Yan M, Wang H, Erickson S, Grewal IS, Dixit VM. Impaired c-Jun amino terminal kinase activity and T cell differentiation in death receptor 6-deficient mice. J Exp Med. 2001;194(10):1441-1448. (Pubitemid 33081519)
111. Liu J, Na S, Glasebrook A, et al. Enhanced CD4+T cell proliferation and Th2 cytokine production in DR6-deficient mice. Immunity. 2001;15(1):23-34. (Pubitemid 32728317)
112. Lee KF, Li E, Huber LJ, et al. Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system. Cell. 1992;69(5):737-749.
113. Tsitsikov EN, Laouini D, Dunn IF, et al. TRAF1 is a negative regulator of TNF signaling. enhanced TNF signaling in TRAF1-deficient mice. Immunity. 2001;15(4):647-657. (Pubitemid 33016449)
114. Missiou A, Kostlin N, Varo N, et al. Tumor necrosis factor receptor-associated factor 1 (TRAF1) deficiency attenuates atherosclerosis in mice by impairing monocyte recruitment to the vessel wall. Circulation. 2010;121(18):2033-2044.
115. Nguyen LT, Duncan GS, Mirtsos C, et al. TRAF2 deficiency results in hyperactivity of certain TNFR1 signals and impairment of CD40-mediated responses. Immunity. 1999;11(3):379-389. (Pubitemid 29463246)
116. Xu Y, Cheng G, Baltimore D. Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. Immunity. 1996;5(5):407-415. (Pubitemid 26423469)
117. Nakano H, Sakon S, Koseki H, et al. Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation. Proc Natl Acad Sci U S A. 1999;96(17):9803-9808. (Pubitemid 29398813)
118. Lomaga MA, Yeh WC, Sarosi I, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin- 1, CD40, and LPS signaling. Genes Dev. 1999;13(8):1015-1024. (Pubitemid 29200984)
119. Naito A, Yoshida H, Nishioka E, et al. TRAF6-deficient mice display hypohidrotic ectodermal dysplasia. Proc Natl Acad Sci U S A. 2002;99(13): 8766-8771. (Pubitemid 34693634)
120. Goeddel DV. Signal transduction by tumor necrosis factor: the Parker B. Francis Lectureship. Chest. 1999;116(1 suppl):69S-73S. (Pubitemid 29340217)
121. Yeh WC, Pompa JL, McCurrach ME, et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science. 1998;279(5358):1954-1958. (Pubitemid 28168653)
122. Kreder D, Krut O, Adam-Klages S, et al. Impaired neutral sphingomyelinase activation and cutaneous barrier repair in FAN-deficient mice. EMBO J. 1999;18(9):2472-2479. (Pubitemid 29213280)
123. Varfolomeev EE, Schuchmann M, Luria V, et al. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity. 1998;9(2):267-276. (Pubitemid 28400040)
124. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity. 1998;8(3):297-303. (Pubitemid 28188890)
125. Hu Y, Baud V, Delhase M, et al. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science. 1999;284(5412):316-320.
126. Li ZW, Chu W, Hu Y, et al. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med. 1999;189(11):1839-1845. (Pubitemid 29272700)
127. Yoshida H, Kong YY, Yoshida R, et al. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell. 1998;94(6):739-750. (Pubitemid 28436006)
128. Hakem R, Hakem A, Duncan GS, et al. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell. 1998;94(3):339-352. (Pubitemid 28376078)
129. Kuida K, Zheng TS, Na S, et al. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature. 1996;384(6607): 368-372. (Pubitemid 26408520)
130. Headon DJ, Emmal SA, Ferguson BM, et al. Gene defect in ectodermal dysplasia implicates a death domain adapter in development. Nature. 2001;414(6866):913-916. (Pubitemid 34024742)
131. Li X. Act1 modulates autoimmunity through its dual functions in CD40L/BAFF and IL-17 signaling. Cytokine. 2008;41(2):105-113. (Pubitemid 351192331)
132. Allen RC, Armitage RJ, Conley ME, et al. CD40 ligand gene defects responsible for X-linked hyper- IgM syndrome. Science. 1993;259(5097): 990-993. (Pubitemid 23080672)
133. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 1994;76(6):969-976. (Pubitemid 24106378)
134. Casal ML, Scheidt JL, Rhodes JL, Henthorn PS, Werner P. Mutation identification in a canine model of X-linked ectodermal dysplasia. Mamm Genome. 2005;16(7):524-531. (Pubitemid 41278429)
135. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97(1):133-144. (Pubitemid 29165896)
136. .Waschke KA, Villani AC, Vermeire S, et al. Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypes. Am J Gastroenterol. 2005;100(5):1126-1133. (Pubitemid 40769052)
137. Magerus-Chatinet A, Neven B, Stolzenberg MC, et al. Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation. J Clin Invest. 2011;121(1):106-112.
138. Hughes AE, Ralston SH, Marken J, et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet. 2000;24(1):45-48. (Pubitemid 30041418)
139. Cundy T, Hegde M, Naot D, et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet. 2002;11(18):2119-2127. (Pubitemid 34994000)
140. Middleton-Hardie C, Zhu Q, Cundy H, et al. Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL. J Bone Miner Res. 2006;21(3):438-445.
141. Salzer U, Chapel HM, Webster AD, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet. 2005;37(8):820-828. (Pubitemid 41077107)
142. Mayne CG, Amanna IJ, Nashold FE, Hayes CE. Systemic autoimmunity in BAFF-R-mutant A/WySnJ strain mice. Eur J Immunol. 2008;38(2): 587-598.
143. Shimomura Y, Sato N, Miyashita A, Hashimoto T, Ito M, Kuwano R. A rare case of hypohidrotic ectodermal dysplasia caused by compound heterozygous mutations in the EDAR gene. J Invest Dermatol. 2004;123(4):649-655. (Pubitemid 39281604)
144. Perez de Diego R, Sancho-Shimizu V, Lorenzo L, et al. Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity. 2010;33(3):400-411.